3IP
REGN icon

3Chopt Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

3Chopt Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-409
Closed -$259K – 244
2025
Q1 		$259K Buy
+409
New +$281K 0.07% 186
2024
Q3 		– Sell
-538
Closed -$565K – 157
2024
Q2 		$565K Buy
+538
New +$522K 0.17% 108
2024
Q1 		– Sell
-599
Closed -$526K – 142
2023
Q4 		$526K Buy
+599
New +$493K 0.19% 102
2023
Q3 		– Sell
-677
Closed -$486K – 119
2023
Q2 		$486K Sell
677
-573
-46% -$442K 0.24% 90
2023
Q1 		$1.03M Sell
1,250
-106
-8% -$79.9K 0.55% 55
2022
Q4 		$978K Buy
+1,356
New +$1M 0.53% 53

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

3Chopt Investment Partners's REGN Position: Q2 2025 in Review

3Chopt Investment Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 409 shares — an estimated $259K sold.

3Chopt Investment Partners first reported a position in REGN in Q4 2022 and held it in 6 quarters. The position peaked at $1.03M in Q1 2023. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • 3Chopt Investment Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • 3Chopt Investment Partners sold 409 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $259K.
  • 3Chopt Investment Partners first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • 3Chopt Investment Partners's Regeneron Pharmaceuticals position peaked at $1.03M in Q1 2023.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on 3Chopt Investment Partners's 13F filing for Q2 2025, filed 24 Jul 2025.